## The real signal: non-dilutive capital plus risk transfer (not just “a $300k check”) Theriva’s February 18, 2026 disclosure is best read as a *risk-off balance-sheet move* disguised as a modest headline upfront: the company secured $300,000 at signing while pushing **all** future development and commercialization cost burden for SYN-020 onto Rasayana. ["received an upfront payment of Three Hundred Thousand Dollars ($300,000)"](0001104659-26-016792|0) ["Rasayana will assume all responsibility and costs"](0001104659-26-016792|2) Just as important, it’s an *exclusive, worldwide* license (with sublicensing rights), which effectively monetizes an asset without Theriva needing to fund the next value-inflection steps itself. ["exclusive worldwide license with the right to grant sublicenses"](0001104659-26-016792|0) ## Embedded upside: milestones + royalties + sublicense participation = asymmetric optionality The economic package creates multiple shots on goal: up to **$16.0 million** of development milestones and up to **$22.0 million** of sales milestones (total up to **$38.0 million**), plus tiered royalties and a share of sublicensing economics. ["development milestone payments of up to an aggregate of $16,000,000"](0001104659-26-016792|0) ["sales milestone payments of up to an aggregate of $22,000,000"](0001104659-26-016792|0) ["eligible for up to $38M"](0001104659-26-016792|2) ["tiered royalties ranging from low to mid single digits"](0001104659-26-016792|0) ["certain percentage of any Sublicense Revenue"](0001104659-26-016792|0) “Between the lines,” that structure matters because it preserves upside exposure (royalties/milestones/sublicense revenue) while minimizing Theriva’s capital at risk—an option-like payoff profile if Rasayana can accelerate clinical progress. ["tiered single-digit royalties"](0001104659-26-016792|2) ["Milestone payments"](0001104659-26-016792|2) ## Strategic refocus: clearing bandwidth for oncology (VCN-01) while still monetizing a non-core GI asset Management explicitly frames the transaction as portfolio prioritization—advancing the GI asset externally while concentrating internal resources on its lead pancreatic cancer program, VCN-01. ["focus on our lead pancreatic cancer program, VCN-01"](0001104659-26-016792|2) That matters because it reduces the “two-front war” dynamic common in small biotechs (multiple programs competing for scarce cash and attention), while keeping a back-end claim on value creation if SYN-020 succeeds under a partner better positioned to fund and execute. ["enable the advancement of this important GI asset"](0001104659-26-016792|2) ["Rasayana will assume all responsibility and costs"](0001104659-26-016792|2) ## Why this can re-rate sentiment quickly: it chips away at near-term financing/dilution overhang In the most recent 8-K *before* the licensing announcement (filed February 12, 2026), Theriva disclosed it failed to reach quorum for a stockholder meeting tied to obtaining approval to issue up to **16,184,560 shares** upon warrant exercise under a prior inducement agreement—i.e., an explicit reminder of dilution mechanics sitting in the background. ["not present... to constitute a quorum"](0001104659-26-013907|0) ["issuance of up to an aggregate of 16,184,560 shares"](0001104659-26-013907|0) Against that context, a licensing deal—however small the upfront—can be interpreted as *non-dilutive financing plus external validation* at a moment when investors are highly sensitive to capital structure pressure. ["received an upfront payment"](0001104659-26-016792|0) ["eligible for... milestones"](0001104659-26-016792|2)

## The real signal: non-dilutive capital plus risk transfer (not just “a $300k check”) Theriva’s February 18, 2026 disclosure is best read as a *risk-off balance-sheet move* disguised as a modest headline upfront: the company secured $300,000 at signing while pushing **all** future development and commercialization cost burden for SYN-020 onto Rasayana. ["received an upfront payment of Three Hundred Thousand Dollars ($300,000)"](0001104659-26-016792|0) ["Rasayana will assume all responsibility and costs"](0001104659-26-016792|2) Just as important, it’s an *exclusive, worldwide* license (with sublicensing rights), which effectively monetizes an asset without Theriva needing to fund the next value-inflection steps itself. ["exclusive worldwide license with the right to grant sublicenses"](0001104659-26-016792|0) ## Embedded upside: milestones + royalties + sublicense participation = asymmetric optionality The economic package creates multiple shots on goal: up to **$16.0 million** of development milestones and up to **$22.0 million** of sales milestones (total up to **$38.0 million**), plus tiered royalties and a share of sublicensing economics. ["development milestone payments of up to an aggregate of $16,000,000"](0001104659-26-016792|0) ["sales milestone payments of up to an aggregate of $22,000,000"](0001104659-26-016792|0) ["eligible for up to $38M"](0001104659-26-016792|2) ["tiered royalties ranging from low to mid single digits"](0001104659-26-016792|0) ["certain percentage of any Sublicense Revenue"](0001104659-26-016792|0) “Between the lines,” that structure matters because it preserves upside exposure (royalties/milestones/sublicense revenue) while minimizing Theriva’s capital at risk—an option-like payoff profile if Rasayana can accelerate clinical progress. ["tiered single-digit royalties"](0001104659-26-016792|2) ["Milestone payments"](0001104659-26-016792|2) ## Strategic refocus: clearing bandwidth for oncology (VCN-01) while still monetizing a non-core GI asset Management explicitly frames the transaction as portfolio prioritization—advancing the GI asset externally while concentrating internal resources on its lead pancreatic cancer program, VCN-01. ["focus on our lead pancreatic cancer program, VCN-01"](0001104659-26-016792|2) That matters because it reduces the “two-front war” dynamic common in small biotechs (multiple programs competing for scarce cash and attention), while keeping a back-end claim on value creation if SYN-020 succeeds under a partner better positioned to fund and execute. ["enable the advancement of this important GI asset"](0001104659-26-016792|2) ["Rasayana will assume all responsibility and costs"](0001104659-26-016792|2) ## Why this can re-rate sentiment quickly: it chips away at near-term financing/dilution overhang In the most recent 8-K *before* the licensing announcement (filed February 12, 2026), Theriva disclosed it failed to reach quorum for a stockholder meeting tied to obtaining approval to issue up to **16,184,560 shares** upon warrant exercise under a prior inducement agreement—i.e., an explicit reminder of dilution mechanics sitting in the background. ["not present... to constitute a quorum"](0001104659-26-013907|0) ["issuance of up to an aggregate of 16,184,560 shares"](0001104659-26-013907|0) Against that context, a licensing deal—however small the upfront—can be interpreted as *non-dilutive financing plus external validation* at a moment when investors are highly sensitive to capital structure pressure. ["received an upfront payment"](0001104659-26-016792|0) ["eligible for... milestones"](0001104659-26-016792|2)